Vibiosphen Vibiosphen combines expertise in microbiology, molecular biology and pharmacology (in vitro and in vivo) with experience in drug R&D in the field of infectious diseases , immunomodulation and host-pathogen interaction in a large company (Sanofi). As a biotechnology company, we conduct research into potential future therapies against multi-resistant bacteria ( E coli, Pseudomona Aeruginosa, Klebsiella, Acinetobacter, Staph aureus..;) including a large panel of predictive models as pneumonia, urinary tract infection, sepsis, septicemia and inflammation. VibioSphen has at disposal, in this high technical and scientific quality environment with A2L2 laboratories and facilities. VibioSphen provides services drawing on cutting-edge technology to create predictive and translational models for studying small molecules, vaccine or biologics